clinical trial · NCT05291689
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)·phase2·completed·n = 39
Inflammatory Bowel DiseasesColitis, UlcerativeMORF-057
brief summary
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
started
Apr 13, 2022
primary completion
Oct 18, 2023
completion
Feb 19, 2025
last updated
Mar 11, 2026
detailed description
The main part of this Phase 2a study will consist of 3 study periods: a Screening Period, a Treatment Period and a Safety Follow-up Period. All participants who complete the open-label Treatment Period will have the opportunity to continue their treatment in an optional 26-week Long-term Extension study after completing the Week 52 assessments.
official title
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol